JP2024540183A - 置換されたフェニルプロピオン酸誘導体及びその使用 - Google Patents
置換されたフェニルプロピオン酸誘導体及びその使用 Download PDFInfo
- Publication number
- JP2024540183A JP2024540183A JP2024525662A JP2024525662A JP2024540183A JP 2024540183 A JP2024540183 A JP 2024540183A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024525662 A JP2024525662 A JP 2024525662A JP 2024540183 A JP2024540183 A JP 2024540183A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- independently selected
- medicamentable
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111293711.9 | 2021-11-03 | ||
| CN202111293711 | 2021-11-03 | ||
| CN202211033065 | 2022-08-26 | ||
| CN202211033065.7 | 2022-08-26 | ||
| PCT/CN2022/129479 WO2023078333A1 (zh) | 2021-11-03 | 2022-11-03 | 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540183A true JP2024540183A (ja) | 2024-10-31 |
| JP2024540183A5 JP2024540183A5 (cg-RX-API-DMAC7.html) | 2026-03-19 |
Family
ID=86240694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525662A Pending JP2024540183A (ja) | 2021-11-03 | 2022-11-03 | 置換されたフェニルプロピオン酸誘導体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250042847A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4428129A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024540183A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240091010A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118055927A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381258A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3235992A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005304A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202334116A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023078333A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024217537A1 (zh) * | 2023-04-21 | 2024-10-24 | 深圳信立泰药业股份有限公司 | 一种叔胺类化合物及其制备方法和医药用途 |
| TW202444710A (zh) * | 2023-05-11 | 2024-11-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種脂蛋白化合物晶型及其製備方法 |
| KR20260041098A (ko) * | 2023-07-21 | 2026-03-26 | 일라이 릴리 앤드 캄파니 | Lp(a) 저하 활성을 갖는 피롤리딘 화합물 |
| CN121548567A (zh) * | 2023-07-21 | 2026-02-17 | 伊莱利利公司 | 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物 |
| CN119490445A (zh) * | 2023-08-15 | 2025-02-21 | 深圳信立泰药业股份有限公司 | 一种酰基类化合物及其制备方法和医药用途 |
| CN122535600A (zh) * | 2023-11-17 | 2026-08-07 | 上海翊石医药科技有限公司 | 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途 |
| CN122270439A (zh) * | 2023-11-20 | 2026-06-23 | 上海齐鲁制药研究中心有限公司 | 一种多环类衍生物、其制备方法和应用 |
| WO2025199298A1 (en) | 2024-03-21 | 2025-09-25 | Eli Lilly And Company | BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a) |
| WO2025237188A1 (zh) * | 2024-05-14 | 2025-11-20 | 石家庄以岭药业股份有限公司 | 一种LP(a)抑制剂化合物及其应用 |
| CN121627662A (zh) * | 2024-09-05 | 2026-03-10 | 成都康弘药业集团股份有限公司 | 芳基丙酸化合物及其制备方法与用途 |
| WO2026061518A1 (zh) * | 2024-09-23 | 2026-03-26 | 上海京新生物医药有限公司 | 一种环状胺衍生物的固体形式、制备方法及药物组合物 |
| WO2026119122A1 (zh) * | 2024-12-02 | 2026-06-11 | 上海喆邺生物科技有限公司 | 一种苯丙酸衍生物及其医药用途 |
| WO2026130347A1 (zh) * | 2024-12-17 | 2026-06-25 | 上海喆邺生物科技有限公司 | 一种吡咯烷衍生物及其在药物中的用途 |
| WO2026130471A1 (zh) * | 2024-12-18 | 2026-06-25 | 江苏恒瑞医药股份有限公司 | 吡咯烷衍生物或其盐的制备方法 |
| CN121609698B (zh) * | 2026-01-30 | 2026-06-02 | 山东京新药业有限公司 | 一种莫伐培林及中间体的制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531312A (ja) * | 2006-03-10 | 2009-09-03 | ファイザー・プロダクツ・インク | ジベンジルアミン化合物および誘導体 |
| JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | 7ティーエム ファーマ エイ/エス | カンナビノイド受容体モジュレーター |
| WO2020247429A1 (en) * | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1962596A (zh) * | 2000-10-11 | 2007-05-16 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
| MXPA03003021A (es) * | 2000-10-11 | 2003-07-14 | Esperion Therapeutics Inc | Compuestos de eter y composiciones para el control del colesterol y usos relacionados. |
| US7371777B2 (en) * | 2001-08-17 | 2008-05-13 | Eisai Co., Ltd. | Cyclic compound and PPAR agonist |
| AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| US7705177B2 (en) * | 2003-12-24 | 2010-04-27 | Esperion Therapuetics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
| EP4469435A1 (en) * | 2022-01-26 | 2024-12-04 | Eli Lilly and Company | Pyrrolidine compounds |
-
2022
- 2022-11-03 WO PCT/CN2022/129479 patent/WO2023078333A1/zh not_active Ceased
- 2022-11-03 TW TW111142050A patent/TW202334116A/zh unknown
- 2022-11-03 KR KR1020247017510A patent/KR20240091010A/ko active Pending
- 2022-11-03 EP EP22889355.8A patent/EP4428129A4/en active Pending
- 2022-11-03 AU AU2022381258A patent/AU2022381258A1/en active Pending
- 2022-11-03 JP JP2024525662A patent/JP2024540183A/ja active Pending
- 2022-11-03 US US18/707,429 patent/US20250042847A1/en active Pending
- 2022-11-03 CA CA3235992A patent/CA3235992A1/en active Pending
- 2022-11-03 MX MX2024005304A patent/MX2024005304A/es unknown
- 2022-11-03 CN CN202280066584.5A patent/CN118055927A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009531312A (ja) * | 2006-03-10 | 2009-09-03 | ファイザー・プロダクツ・インク | ジベンジルアミン化合物および誘導体 |
| JP2011506410A (ja) * | 2007-12-10 | 2011-03-03 | 7ティーエム ファーマ エイ/エス | カンナビノイド受容体モジュレーター |
| WO2020247429A1 (en) * | 2019-06-07 | 2020-12-10 | Eli Lilly And Company | Pyrrolidine compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4428129A1 (en) | 2024-09-11 |
| WO2023078333A1 (zh) | 2023-05-11 |
| MX2024005304A (es) | 2024-05-17 |
| AU2022381258A1 (en) | 2024-05-02 |
| US20250042847A1 (en) | 2025-02-06 |
| TW202334116A (zh) | 2023-09-01 |
| CN118055927A (zh) | 2024-05-17 |
| EP4428129A4 (en) | 2025-05-07 |
| WO2023078333A8 (zh) | 2023-08-10 |
| KR20240091010A (ko) | 2024-06-21 |
| CA3235992A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118055927A (zh) | 一种取代的苯丙酸衍生物及其用途 | |
| JP7813970B2 (ja) | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 | |
| JP7508422B2 (ja) | ピロリジン化合物 | |
| JP7579805B2 (ja) | アミノ酸化合物の剤形およびレジメン | |
| EP4332102A1 (en) | Isoquinolone compound and use thereof | |
| JP3993651B2 (ja) | シクロプロパクロメンカルボン酸誘導体 | |
| JPH07502265A (ja) | 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体 | |
| JPH07223953A (ja) | 中枢神経系疾患治療用薬剤組成物 | |
| JP2026502915A (ja) | 補体因子b阻害剤 | |
| JP2024032976A (ja) | アデノシン受容体アンタゴニストおよびその使用 | |
| WO2014013469A1 (en) | Carbamate/urea derivatives | |
| AU2024267706A1 (en) | Crystal form of lipoprotein compound and preparation method therefor | |
| JP2024535804A (ja) | 置換された1,4-ジヒドロ-1,6-ナフチミダミド及びその使用 | |
| JPS6112907B2 (cg-RX-API-DMAC7.html) | ||
| CN115677507B (zh) | 氟比洛芬衍生物及其在药物中的应用 | |
| JP7701475B2 (ja) | アルキルカルボン酸化合物及びその使用 | |
| JP2024535126A (ja) | 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途 | |
| JP2024533411A (ja) | ハロゲン置換のピリダジノン系化合物及びその使用 | |
| PT93045A (pt) | Processo para a preparacao de derivados de pirrolidina e de composicoes farmaceuticas que os contem | |
| KR20150135281A (ko) | 페닐 유도체 | |
| TW202515554A (zh) | Slc6a19功能之含雙環雜芳基之哌啶抑制劑 | |
| JP3786983B2 (ja) | ピロリジノン誘導体 | |
| CN114621189B (zh) | 一种内酰胺类衍生物及其用途 | |
| WO2001000616A1 (en) | Cholesterol biosynthesis inhibitors containing as the active ingredient aromatic compounds bearing cyclic amino groups | |
| Ohno et al. | Synthesis of the optical isomers of 4-[1-(4-tert-butylphenyl)-2-oxo-pyrrolidine-4-yl] methyloxybenzoic acid (S-2) and their biological evaluation as antilipidemic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251031 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251031 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260310 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20260310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260331 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260622 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20260701 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260701 |